From genetic association to molecular mechanism.

From genetic association to molecular mechanism.

Over the past 3 years, there has been a dramatic increase in the number of confirmed type 2 diabetes (T2D) susceptibility loci, most arising through the implementation of genome-wide association studies (GWAS). However, progress toward the understanding of disease mechanisms has been slowed by modes...

Bibliográfalaš dieđut
Váldodahkkit:	van de Bunt, M, Gloyn, A
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2010

Geahča maid

Translating genetic association signals for diabetes and metabolic traits into molecular mechanisms for disease
Dahkki: Rees, MG, et al.
Almmustuhtton: (2014)

Bridging the gap between genetic associations and molecular mechanisms for type 2 diabetes.
Dahkki: Ng, H, et al.
Almmustuhtton: (2013)

A tale of two glucose transporters: how GLUT2 re-emerged as a contender for glucose transport into the human beta cell.
Dahkki: van de Bunt, M, et al.
Almmustuhtton: (2012)

A tale of two glucose transporters: How GLUT2 re-emerged as a contender for glucose transport into the human beta cell
Dahkki: Van De Bunt, M, et al.
Almmustuhtton: (2012)

Monogenic disorders of the pancreatic β-cell: Personalizing treatment for rare forms of diabetes and hypoglycemia
Dahkki: van de Bunt, M, et al.
Almmustuhtton: (2007)

Genetics for Endocrinologists: The Molecular Genetic Basis of Endocrine Disorders.
Dahkki: McCarthy, M, et al.
Almmustuhtton: (2003)

GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus.
Dahkki: McCulloch, L, et al.
Almmustuhtton: (2011)

GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: Implications for understanding genetic association signals at this locus
Dahkki: McCulloch, L, et al.
Almmustuhtton: (2011)

Gene duplications resulting in over expression of glucokinase are not a common cause of hypoglycaemia of infancy in humans.
Dahkki: van de Bunt, M, et al.
Almmustuhtton: (2008)

Glucokinase (GCK) and other susceptibility genes for beta-cell dysfunction: the candidate approach.
Dahkki: Gloyn, A, et al.
Almmustuhtton: (2008)

The pancreatic β cell: Recent insights from human genetics
Dahkki: Thomsen, S, et al.
Almmustuhtton: (2014)

The pancreatic β cell: recent insights from human genetics.
Dahkki: Thomsen, S, et al.
Almmustuhtton: (2014)

Mechanisms of genome regulation in human islets and their role in the pathogenesis of type 2 diabetes
Dahkki: van de Bunt, G, et al.
Almmustuhtton: (2014)

The genetics of diabetes: A progress report
Dahkki: Gloyn, A
Almmustuhtton: (2001)

Developing a network view of type 2 diabetes risk pathways through integration of genetic, genomic and functional data
Dahkki: Fernández-Tajes, J, et al.
Almmustuhtton: (2019)

Genetics: how the UKPDS contributed to determining the genetic landscape of Type 2 diabetes.
Dahkki: Gloyn, A, et al.
Almmustuhtton: (2008)

An alternative effector gene at the type 2 diabetes-associated TCF7L2 locus?
Dahkki: van de Bunt, M
Almmustuhtton: (2016)

The genetics of type 2 diabetes.
Dahkki: Gloyn, A, et al.
Almmustuhtton: (2001)

RD Lawrence Lecture 2009. Old genes, new tricks: learning about blood glucose regulation from naturally occurring genetic variation in humans.
Dahkki: Gloyn, A
Almmustuhtton: (2009)

Mutations in HHEX are not a common cause of monogenic forms of beta cell dysfunction.
Dahkki: Minton, J, et al.
Almmustuhtton: (2007)

Prevalence of GCK mutations in individuals screened for fasting hyperglycaemia.
Dahkki: Gloyn, A, et al.
Almmustuhtton: (2009)

Prevalence of glucokinase (GCK) mutations in people with elevated fasting glucose levels: implications for clinical trials
Dahkki: Gloyn, A, et al.
Almmustuhtton: (2007)

Defining the genetic aetiology of monogenic diabetes can improve treatment.
Dahkki: Gloyn, A, et al.
Almmustuhtton: (2006)

Genetic and molecular mechanisms of hydrocephalus
Dahkki: Xuehai Deng, et al.
Almmustuhtton: (2025-01-01)

Human genetics as a model for target validation: finding new therapies for diabetes
Dahkki: Thomsen, S, et al.
Almmustuhtton: (2017)

Monogenic β-cell dysfunction in children: Clinical phenotypes, genetic etiology and mutational pathways
Dahkki: Waterfield, T, et al.
Almmustuhtton: (2008)

Genetic association and Mendelian randomization for hypothyroidism highlight immune molecular mechanisms
Dahkki: Samuel Mathieu, et al.
Almmustuhtton: (2022-09-01)

Developing a network view of type 2 diabetes risk pathways through integration of genetic, genomic and functional data
Dahkki: Juan Fernández-Tajes, et al.
Almmustuhtton: (2019-03-01)

Genetic association with autoimmune diseases identifies molecular mechanisms of coronary artery disease
Dahkki: Sophia Kerns, et al.
Almmustuhtton: (2024-09-01)

Hypertrophic cardiomyopathy: from molecular and genetic mechanisms to clinical management
Dahkki: Watkins, H
Almmustuhtton: (2001)

Potential Molecular Mechanisms of Alzheimer’s Disease from Genetic Studies
Dahkki: Martin Nwadiugwu, et al.
Almmustuhtton: (2023-04-01)

Genetic and Molecular Mechanisms in Brugada Syndrome
Dahkki: Errol Moras, et al.
Almmustuhtton: (2023-07-01)

Molecular mechanisms and genetics of Alzheimer’s disease
Dahkki: Öztan Gözde, et al.
Almmustuhtton: (2023-05-01)

The Genetic and Molecular Mechanisms of Congenital Hyperinsulinism
Dahkki: Sonya Galcheva, et al.
Almmustuhtton: (2019-02-01)

Molecular mechanisms and genetic regulation in atherosclerosis
Dahkki: Ampadu-Okyere Jackson, et al.
Almmustuhtton: (2018-12-01)

Molecular genetic mechanisms of ovarian organization and development
Dahkki: V. G. Zenkina, et al.
Almmustuhtton: (2018-07-01)

Molecular characterization of lugdunin inactivation mechanisms and their association with Staphylococcus lugdunensis genetic types
Dahkki: Lee-Chung Lin, et al.
Almmustuhtton: (2024-04-01)

SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells.
Dahkki: Kailey, B, et al.
Almmustuhtton: (2012)

Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour?
Dahkki: Rees, MG, et al.
Almmustuhtton: (2013)

Small molecular glucokinase activators: Has another new anti-diabetic therapeutic lost favour?
Dahkki: Rees, MG, et al.
Almmustuhtton: (2014)